Amryt Pharma Plc（纳斯达克股票代码：AMYT）空头利率更新

Amryt Pharma plc (NASDAQ:AMYT – Get Rating) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 121,200 shares, a growth of 56.2% from the February 28th total of 77,600 shares. Based on an average trading volume of 646,300 shares, the days-to-cover ratio is presently 0.2 days.

Amryt Pharma Trading Down 0.3 %

Amryt Pharma stock opened at $14.55 on Wednesday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.57 and a quick ratio of 0.94. Amryt Pharma has a fifty-two week low of $6.41 and a fifty-two week high of $14.77. The firm has a fifty day moving average price of $14.61 and a two-hundred day moving average price of $10.13.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Maxim Group cut Amryt Pharma from a "buy" rating to a "hold" rating in a research report on Tuesday, January 10th. Canaccord Genuity Group reissued a "hold" rating and issued a $17.00 price target (down previously from $19.00) on shares of Amryt Pharma in a research note on Tuesday, January 10th. SVB Leerink lowered shares of Amryt Pharma from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $19.00 to $14.50 in a research report on Monday, January 9th. HC Wainwright downgraded shares of Amryt Pharma from a "buy" rating to a "neutral" rating in a research report on Wednesday, January 18th. Finally, Cantor Fitzgerald lowered shares of Amryt Pharma from an "overweight" rating to a "neutral" rating and reduced their price objective for the company from $25.00 to $14.75 in a research note on Tuesday, January 10th. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $15.42.

Institutional Trading of Amryt Pharma

Hedge funds have recently added to or reduced their stakes in the business. Nantahala Capital Management LLC bought a new stake in shares of Amryt Pharma in the first quarter valued at approximately $8,862,000. Renaissance Technologies LLC grew its position in Amryt Pharma by 44.1% in the 1st quarter. Renaissance Technologies LLC now owns 25,800 shares of the company's stock worth $213,000 after purchasing an additional 7,900 shares during the last quarter. Hsbc Holdings PLC bought a new position in shares of Amryt Pharma during the 1st quarter worth about $202,000. Woodline Partners LP raised its position in shares of Amryt Pharma by 262.7% during the first quarter. Woodline Partners LP now owns 480,363 shares of the company's stock valued at $3,973,000 after buying an additional 347,925 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in shares of Amryt Pharma by 120.2% in the first quarter. Bank of America Corp DE now owns 68,779 shares of the company's stock valued at $569,000 after buying an additional 37,542 shares during the period. Institutional investors own 71.31% of the company's stock.

Amryt Pharma Company Profile

(Get Rating)

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia.

Recommended Stories

• Get a free copy of the StockNews.com research report on Amryt Pharma (AMYT)
• 3 Undervalued Dividend Payers For Volatile Market Conditions
• 3 More Downgrades To Put On Your Buy List
• Triple-Digit Gains Are In Store For The Lovesac Company
• 3 Oversold Large Caps With Rebound Potential
• After an Earnings Blowout, Is Ciena Stock a Buying Opportunity?

Receive News & Ratings for Amryt Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma and related companies with MarketBeat.com's FREE daily email newsletter.